Diabetes & Endocrinology
Latest news
531 articles · 20 / page
Harnessing Digital Health Technologies in Obesity Management: Insights from a Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials
Digital health interventions show modest but clinically meaningful reductions in waist circumference for overweight and obese adults, highlighting their potential as adjuncts in obesity care despite limited effects on weight and behavior.
Short-Term Kanzaki Mulberry Leaf and Water Chestnut Tea Intake Effectively Suppresses Postprandial Blood Glucose Variability: A Randomized Crossover Trial
A 2-week randomized, double-blind, placebo-controlled crossover trial demonstrated that Kanzaki mulberry leaf and water chestnut tea significantly reduces postprandial glucose variability without adverse safety signals, supporting its poten
Microbiota-Mediated Weight Loss: Insights from the WLM3P Multicomponent Program in Obesity
The WLM3P weight loss program significantly remodels gut microbiota, enriching beneficial bacteria such as Faecalibacterium, which associates with improved fat and visceral fat loss in adults with obesity compared to standard low-carb diets
The Protective Effects of High-Intensity Interval Training on Cardiovascular, Neurological, and Metabolic Health
High-intensity interval training (HIIT) offers significant protective benefits for the cardiovascular, neurological, and metabolic systems, promoting overall health and disease prevention.
Recent Advances in High-Intensity Interval Training: Cardiovascular, Metabolic, Diabetes, and Neuroprotective Effects
This review synthesizes recent evidence on the benefits of high-intensity interval training (HIIT) on cardiovascular health, diabetes management, metabolic function, and neuroprotection, highlighting mechanistic insights and clinical implic
Top 10 Weight Loss Pitfalls and How to Avoid Them: A Science-Based Guide
Uncover the ten most common weight loss misconceptions and pitfalls, and learn scientifically grounded practices to achieve sustainable, healthy fat loss.
Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena
Eli Lilly’s oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promi
Debunking Weight Loss Myths: Avoid These Pitfalls for More Effective and Healthy Weight Loss
This article explores common weight loss misconceptions, offering scientific insights and strategies for safe and sustainable fat loss.
Debunking 7 Common Weight Loss Myths: What You Need to Know for Healthy Fat Loss
Explore seven prevalent misconceptions about weight loss—from ignoring obesity as a disease to the dangers of rapid slimming—founded on medical evidence and expert advice to guide safe and effective weight management.
Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
Obicetrapib Shows Promise in Slowing Alzheimer’s Disease Progression Through Lipid Modulation
Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.
Long-Term Metformin Use Linked to Reduced Risk of Age-Related Macular Degeneration in Diabetic Patients
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes
Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabe
Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.
Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial
The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.
SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes
Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.
The Long-Term Legacy of Atorvastatin: Insights from the 20-Year ASCOT-Legacy Follow-Up
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial
Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.
Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818
Improving Patient Safety: The Role of Deprescribing Diabetes Medication in Older Adults
This study examines the effectiveness of physician academic detailing combined with previsit patient activation to increase diabetes medication deprescribing amongst older adults, aiming to reduce hypoglycemia-related complications.
Browse by specialty
Open language-specific specialty feeds and department pages.